Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for China SXT Pharmaceuticals's 14-Day RSI or its related term are showing as below:
STU:2RY1's 14-Day RSI is ranked better than 97.99% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 46.95
vs STU:2RY1: 100.00
China SXT Pharmaceuticals (STU:2RY1) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
China SXT Pharmaceuticals 14-Day RSI Related Terms
STU:2RY1 vs CBIH, UPC, NPHC: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's 14-Day RSI falls into.
China SXT Pharmaceuticals (STU:2RY1) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (STU:2RY1) has a 14-Day RSI of 100.00 as of Jul. 29, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on China SXT Pharmaceuticals and its competitors. According to the industry distribution chart, China SXT Pharmaceuticals ranks #21 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is China SXT Pharmaceuticals' 14-Day RSI too high?
China SXT Pharmaceuticals' current 14-Day RSI is 100.00. The Drug Manufacturers industry median 14-Day RSI is 46.95. China SXT Pharmaceuticals' value of 100.00 is 113% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #21 out of 1047 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' 14-Day RSI compare to CBIH and UPC?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #21 out of 1047 companies for 14-Day RSI. This places China SXT Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 46.95. China SXT Pharmaceuticals' value of 100.00 is 113% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 46.95, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current 14-Day RSI of 100.00 is 113% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 46.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current 14-Day RSI is 100.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current 14-Day RSI of 100.00. The stock's GF Value™ is €13,666.67, compared to a current price of €384.00 — trading 97.2% below its estimated fair value. The current 14-Day RSI is 100.00 and 113% above the Drug Manufacturers industry median of 46.95. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current 14-Day RSI is 100.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (STU:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €384.00 is trading 97.2% below its estimated GF Value™ of €13,666.67.
Key valuation signals for STU:2RY1:
14-Day RSI: 100.00
GF Value™: €13,666.67 vs. price of €384.00 (97.2% below fair value)
Industry Position: 113% above the Drug Manufacturers median (#21 of 1047)
No single metric tells the full story. See the STU:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score
Get the complete analysis for STU:2RY1
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RY1 has been successfully added to your 
